Somatostatin Receptor clinical trials at UCLA

1 research study open to eligible people

RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
open to eligible people ages 18 years and up
The primary objectives are to determine the recommended Phase 2 dose (RP2D) and optimal treatment regimen, characterize safety and tolerability, and evaluate preliminary efficacy of RYZ401 in subjects with NETs and other selected solid tumors expressing SSTRs.
Los Angeles, California and other locations

Last updated: October 30, 2026